Skip to content

Study · Animal study (in vivo) · rat · 2005

4 results

Protective effect of serum thymic factor, FTS, on cephaloridine-induced nephrotoxicity in rats.

Kohda Y, Matsunaga Y, Yonogi K, Kawai Y, Awaya A, Gemba M

Biological & pharmaceutical bulletin1 Nov 2005Cited by 3 (Europe PMC)

PMID16272694 (opens in a new tab)DOI10.1248/bpb.28.2087 (opens in a new tab)PepBankPUB-16272694
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats, FTS pretreatment attenuated cephaloridine-induced renal dysfunction.

    In plain wordsIn rats, FTS reduced kidney dysfunction compared with cephaloridine alone.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    DecreaseRenal dysfunction
    Study

    ratn: not reported in source

    Cephaloridine nephrotoxicity in male Sprague-Dawley rats
    Comparator
    Cephaloridine without FTS
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    50 microg/kg · intravenousAs given in this study (rat).

    Source sentences

    Summary
    Pretreatment of rats with FTS (50 microg/kg, i.v.) attenuated the CER-induced renal dysfunction and pathological damage.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats, FTS pretreatment attenuated cephaloridine-induced pathological damage.

    In plain wordsIn rats, FTS reduced kidney tissue damage compared with cephaloridine alone.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    DecreaseRenal pathological damage
    Study

    ratn: not reported in source

    Cephaloridine nephrotoxicity in male Sprague-Dawley rats
    Comparator
    Cephaloridine without FTS
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    50 microg/kg · intravenousAs given in this study (rat).

    Source sentences

    Summary
    Pretreatment of rats with FTS (50 microg/kg, i.v.) attenuated the CER-induced renal dysfunction and pathological damage.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In rats, FTS suppressed cephaloridine-induced renal ERK activation.

    In plain wordsIn rats, FTS reduced kidney ERK activation compared with cephaloridine alone.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    DecreaseRenal ERK activation
    Study

    ratn: not reported in source

    Cephaloridine nephrotoxicity in male Sprague-Dawley rats
    Comparator
    Cephaloridine without FTS
    Outcome group
    Receptor activity and mechanism · Kidney and urinary
    Studied dose
    50 microg/kg · intravenousAs given in this study (rat).

    Source sentences

    Summary
    FTS also suppressed CER-induced ERK activation in the kidney.
  4. 04LabIn vitro (cells)Efficacy outcome

    In LLC-PK1 cells, FTS reduced cephaloridine-induced injury measured by LDH leakage.

    In plain wordsIn cells, FTS reduced injury compared with cephaloridine alone.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    DecreaseCell injury measured by LDH leakage
    Study

    n: not reported in source

    LLC-PK1 cells exposed to cephaloridine
    Comparator
    Cephaloridine without FTS
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro treatment of the established cell line, LLC-PK1 cells, with FTS significantly ameliorated CER-induced cell injury, as measured by lactate dehydrogenase (LDH) leakage.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.